Health Care/Hospital Global News & Press Release Distribution

Health Care/Hospital

All
APAC

Baird Medical and ExcelFin Acquisition Corp Announce Effectiveness of Registration Statement

FORT MILL, S.C., Sept. 5, 2024 /PRNewswire/ -- Betters Medical Investment Holdings Limited ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider inChina, and ExcelFin Acquisition Corp. ("ExcelFin") (NASDAQ:XFIN

2024-09-06 05:23 2837

A Small Step towards a Big Mission! World's First! UltraDx Received First Clinical Approval of Single-Molecule Analyzer, in China

SHANGHAI, Sept. 5, 2024 /PRNewswire/ -- UltraDx Bio is proud to announce that its flagship product, the UD-X™ Fully Automated Single-Molecule Array Fluorescence Immunoassay Analyzer, has received its first clinical registration approval inChina. This groundbreaking achievement is now officially l...

2024-09-05 20:35 1939

A Small Step towards a Big Mission! World's First! UltraDx Received First Clinical Approval of Single-Molecule Analyzer, in China

Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation

* Medera is a clinical-stage biotechnology company focused on targeting difficult-to-treat cardiovascular diseases using a range of next-generation gene- and cell-based approaches in combination with bioengineered human mini-heart drug discovery and screening technology platforms * Transactio...

2024-09-05 20:00 2440

Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration

NANJING, China, Sept. 5, 2024 /PRNewswire/ -- On September 2, 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that Sanbexin Sublingual Tablets (Edaravone and Dexborneol sublingual tablets), an innovative drug for stroke, has been granted the Breakthrough Therapy designation by the U....

2024-09-05 13:49 1196

Grand launch | Sanyou Bio monkeypox antibody made a great breakthrough

SHANGHAI, Sept. 4, 2024 /PRNewswire/ -- On August 28, 2024, Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. announced the launch of 65 kinds of monkeypox antibodies, antigens and cell lines, which has won wide praise from the public. Monkeypox human antibody, as the core product launched by Sanyo...

2024-09-05 08:00 1057

Harrison.ai launches world leading AI model to transform healthcare

Harrison.rad.1 significantly outperforms other major models on radiology tasks The new model is being made accessible to select healthcare professionals and regulators to open up the conversation on responsible use of AI in healthcare SYDNEY, Sept. 4, 2024 /PRNewswire/ -- Healthcare AI technolog...

2024-09-04 21:30 1814

Harrison.ai launches world leading AI model to transform healthcare

Samyang Corporation Completes Specialty Plant, Establishes Korea's Largest Allulose Production Facility

* Completion of the Specialty (high-functional ingredients) Plant producing allulose and prebiotics ingredients * Total floor area of 22,150m2, annual specialty ingredients production capacity of 25,000 tons, with an investment of approximatelyKRW 140 billion * Largest allulose production...

2024-09-04 20:30 2229

Samyang Corporation Completes Specialty Plant, Establishes Korea's Largest Allulose Production Facility

LakeShore Biopharma Announces Leadership Transitions

GAITHERSBURG, Md., Sept. 4, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for ...

2024-09-04 20:00 1180

Waterdrop Inc. Announces Second Quarter 2024 Unaudited Financial Results and a Special Cash Dividend

BEIJING, Sept. 4, 2024 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the three and six months endedJune...

2024-09-04 18:18 2613

HKBU develops Chinese medicine for ulcerative colitis approved by National Medical Products Administration for clinical trial

HONG KONG, Sept. 4, 2024 /PRNewswire/ -- The Centre for Chinese Herbal Medicine Drug Development (CDD) at Hong KongBaptist University (HKBU) has achieved a significant milestone in developing a novel Chinese herbal formulation for ulcerative colitis remission maintenance. Following a submission o...

2024-09-04 15:13 1396

HKBU develops Chinese medicine for ulcerative colitis approved by National Medical Products Administration for clinical trial

Acepodia Enters Strategic Clinical Collaboration with Pfizer to Accelerate Development of Antibody-Cell Conjugation-Based Cell Therapies in Autoimmune Diseases

* Through Pfizer Ignite, Acepodia will gain access to Pfizer's resources, scale and expertise as the company broadens the application of its platform beyond oncology into autoimmune diseases * Pfizer Ignite will also provide strategic advisory support for Acepodia's ongoing clinical programs,...

2024-09-04 05:00 1590

Immune Phenotyping Identified as Promising Predictive Biomarker by Lunit AI in Biliary Tract Cancer - New publication in CCR

* AI-based tumor microenvironment classification utilizing Lunit SCOPE IO® shows promise for guiding treatment decisions in advanced BTC SEOUL, South Korea ,Sept. 3, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, to...

2024-09-03 21:00 1461

Immune Phenotyping Identified as Promising Predictive Biomarker by Lunit AI in Biliary Tract Cancer - New publication in CCR

FIT KING's Award-Winning Innovation: The Recovery Pro Full Leg Compression Massage Boots

NEW YORK, Sept. 3, 2024 /PRNewswire/ -- FIT KING is delighted to announce the success of its latest product, the Recovery Pro Full Leg Compression Massage Boots, which was launched in June. As a leading brand in smart home rehabilitation solutions, FIT KING's dedication to enhancing muscle recove...

2024-09-03 20:00 949

FIT KING's Award-Winning Innovation: The Recovery Pro Full Leg Compression Massage Boots

Biostar Announces Completion of Patient Recruitment for US Phase 1 Clinical Study of Utidelone Capsule

SAN FRANCISCO, Sept. 3, 2024 /PRNewswire/ -- Biostar Pharma, Inc., the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. which is a synthetic biology driven biopharma company focusing on the discovery, development and commercialization of innovative oncology drugs, is pleased to announce...

2024-09-03 20:00 1217

Skyline Therapeutics' Novel Gene Therapy SKG1108 Receives FDA Orphan Drug Designation for Retinitis Pigmentosa

BOSTON and SHANGHAI, Sept. 3, 2024 /PRNewswire/ -- Skyline Therapeutics, an innovation-driven gene therapy company committed to developing unique and novel solutions for rare and severe diseases, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) fo...

2024-09-03 18:00 1063

QingSong Health Chairman Speaks at Global Ethics Forum in Geneva: Advancing Ethical Leadership in Healthcare

GENEVA, Sept. 3, 2024 /PRNewswire/ -- At the Global Ethics Forum, a leading platform that convenes stakeholders from various sectors to discuss peace, sustainability, and ethical leadership, the Chairman of QingSong Health,China's premier healthcare solutions technology platform, delivered a comp...

2024-09-03 16:27 1260

GC Biopharma and Hanmi Pharmaceutical Receives IND Clearance for Phase 1/2 Clinical Trial from the U.S. FDA

* Co-development of innovative new drug for the treatment of Fabry disease as "the world's first once-monthly subcutaneous treatment" * Improves efficacy compared to existing treatment for kidney function, vascular disease, and peripheral nerve disorders YONGIN, South Korea, Sept. 3, 2024 /PR...

2024-09-03 15:59 1193

Caliway Announces the Initiation of Subject Recruitment in CBL-514 Phase 2b Study for Dercum's Disease

NEW TAIPEI CITY, Sept. 3, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that the subject recruitment of CBL-514 Phase2b study for Dercum's disease (CBL-0202 DD Phase2b study, NCT06303570) has been initiated. The study results are anticipated in Q4 2025. CBL-0202DD study i...

2024-09-03 15:18 1189

Simcere Zaiming collaborates with TargetRx to introduce a third-generation ALK inhibitor

NANJING, China, Sept. 2, 2024 /PRNewswire/ -- On September 02, 2024, Simcere Zaiming, an innovative oncology company under Simcere Pharmaceutical Group (2096.HK), announced a collaboration agreement with Shenzhen TargetRx Inc. The partnership focuses on the ALK/ROS1 dual receptor tyrosine kinase ...

2024-09-02 20:24 1533

Jacobio Out-licensed KRAS G12C Inhibitor Glecirasib and SHP2 Inhibitor JAB-3312 to Allist in China

BEIJING and SHANGHAI and BOSTON, Aug. 30, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that it has granted theChina rights (including mainland China, Hong Kong, Macau, and Taiwan) of KRAS G12C inhibitor glecirasi...

2024-08-30 19:34 5624

Jacobio Out-licensed KRAS G12C Inhibitor Glecirasib and SHP2 Inhibitor JAB-3312 to Allist in China

1 ... 14 15 161718 19 20 ... 277